文献速递鼻科

度普利尤单抗单药治疗日本慢性鼻窦炎伴鼻息肉患者的有效性与安全性

Effectiveness and Safety of Dupilumab Monotherapy in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyps.
PubMed 文献 · Laryngoscope · 2025-08-30

这项4期、开放标签、单臂、多中心研究纳入25例标准治疗(含全身糖皮质激素和/或手术)控制不佳的日本慢性鼻窦炎伴鼻息肉成人患者,评估每2周皮下注射度普利尤单抗300 mg单药治疗。第24周92.0%的患者为应答者,鼻息肉评分、鼻塞严重度评分及Lund-Mackay评分均较基线下降,52周内耐受性良好。

要点

  • 第24周时23例(92.0%)患者对度普利尤单抗单药治疗有应答。
  • 第24周双侧内镜鼻息肉评分平均较基线下降2.4分。
  • 52周内16例(69.6%)发生治疗中出现的不良事件,多为轻度。

核心结论

  • 度普利尤单抗单药治疗对有症状的日本慢性鼻窦炎伴鼻息肉患者有效且耐受性良好。

研究设计与样本

  • 4期、开放标签、单臂、多中心研究,纳入25例标准治疗(包括全身糖皮质激素和/或手术)控制不佳的慢性鼻窦炎伴鼻息肉成人患者。

主要发现

  • 第24周时23例(92.0%)患者被认为是度普利尤单抗应答者。
  • 第24周时双侧内镜鼻息肉评分较基线平均变化为-2.4,鼻塞严重度评分较基线平均变化为-1.58,Lund-Mackay评分较基线平均变化为-5.6。
  • 52周内16例(69.6%)参与者发生治疗中出现的不良事件(TEAE),大多数TEAE为轻度,中度TEAE报告于5例(21.7%)参与者,重度TEAE报告于1例(4.3%)参与者。

关键数值与推荐

  • 皮下注射度普利尤单抗300 mg,每2周一次;第24周疾病稳定(第16周和第24周鼻息肉评分[NPS]较基线改善≥2分)的参与者可将给药间隔调整为每4周一次。
  • 主要终点为第24周应答者的比例。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The randomized, double-blind, placebo-controlled LIBERTY SINUS-24 and SINUS-52 studies demonstrated that dupilumab is effective for chronic rhinosinusitis with nasal polyps (CRSwNP) when used with an intranasal corticosteroid (INCS); however, INCSs are not approved for CRSwNP in Japan. The current study aimed to investigate the effectiveness and safety of dupilumab monotherapy in Japanese individuals with CRSwNP. METHODS: This phase 4, open-label, single-arm, multicenter study enrolled adult individuals with CRSwNP inadequately controlled with standard care therapies, including systemic corticosteroids and/or surgery. Subcutaneous dupilumab 300 mg was administered every 2 weeks; in participants with stable disease at week 24 (improvement of ≥ 2 points in the Nasal Polyp Score [NPS] from baseline at weeks 16 and 24), the dosing interval could be modified to every 4 weeks. The primary endpoint was the proportion of responders at week 24. RESULTS: The study included 25 individuals with CRSwNP (mean ± standard deviation age of 53.4 ± 13.6 years; 60.0% male). At week 24, 23 participants (92.0%) were considered responders to dupilumab. Reductions from baseline to week 24 in bilateral endoscopic NPS (mean change -2.4), nasal congestion severity score (-1.58), and Lund-Mackay scores (-5.6) were observed with dupilumab. Dupilumab was well tolerated; over 52 weeks, 16 participants (69.6%) experienced a treatment-emergent adverse event (TEAE). Most TEAEs were mild in severity; moderate and severe TEAEs were reported in five (21.7%) and one (4.3%) participant, respectively. CONCLUSION: Dupilumab monotherapy was effective and well tolerated in Japanese individuals with symptomatic CRSwNP. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05049122.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Fujieda S, Takabayashi T, Ohta N, et al. Effectiveness and Safety of Dupilumab Monotherapy in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyps. Laryngoscope. 2025. PMID: 40884290. doi:10.1002/lary.70037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。